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Background: Surveillance of antimicrobial resistance (AMR) is an essential
component of any strategy to mitigate AMR and needs regular evaluation to
ensure its effectiveness. A first step for any evaluation is to describe the system
and context. In this study, we aimed to characterise and map the surveillance
system for AMR and antimicrobial use (AMU) in the United Kingdom (UK)
using a One Health (OH) approach and to identify integration points in the
system.
Methods: To describe the surveillance system for AMR/AMU, international
guidelines for establishing surveillance systems for AMR and AMU were used.
A review of the literature was conducted to collect information on the differ-
ent parameters identified.
Results: Multiple data collection systems exist for AMU and AMR in humans,
animals and food. Each sector is responsible for the planning, implementa-
tion, analysis and reporting of its own surveillance for AMR and AMU. Some
cross-sectoral collaborative activities exist such as the UK AMR contingency
plan and the publication of UK OH reports; there are opportunities for further
integration such as the harmonisation of data analyses methods and interpre-
tation across sectors and the publication of joint surveillance reports.
Conclusion: This overview of key stakeholders, data collection streams,
reporting, linkages within and across sectors and international monitoring
forms an important basis for future evaluation of the UK AMR/AMU surveil-
lance system from a OH perspective.
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INTRODUCTION
Antimicrobial resistance (AMR) is a global health
threat that has been met with intensified response
from national and international organisations.1,2 In
2015, WHO developed the Global Action Plan (GAP) on
AMR in collaboration with the OIE and the Food and
Agriculture Organisation (FAO).3 This GAP required all
countries to develop a National Action Plan (NAP) by
2017 and included five strategic objectives that pro-
vided a framework for NAPs to combat AMR. More-
over, in the UN General Assembly in 2016, heads of
states committed to support and implement the GAP
at national, regional and global levels.1
1 https://www.un.org/pga/71/wp-content/uploads/sites/40/2016/09/
DGACM_GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108E.pdf.
Surveillance is an essential component in the
response to AMR and one of the strategic GAP objec-
tives. It allows countries to collect data on AMU and
AMR prevalence, monitor trends, detect emergence
of new resistance, provide necessary data to conduct
risk analysis and inform policy recommendations.4
The inter-connected drivers of AMR that are active
across sectors mean that surveillance data need to
be collected from humans, animals, food and the
environment in a coordinated and harmonised way
to allow cross-sectoral analyses. This approach is
also known as One Health (OH) surveillance. In order
to assist countries in the development of integrated
surveillance systems, the WHO advisory Group on
Integrated Surveillance of AMR (AGISAR) developed in
2017 a guidance for the application of a OH approach
to surveillance of AMR in foodborne bacteria.5
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The government of the United Kingdom (UK)
recognises the global threat of AMR and the need
for coordinated national and international actions
across sectors for risk mitigation.6 Therefore, a 5-year
AMR strategy based on a OH approach was developed
in 2013, which was renewed in 2019.7,8 The strategy
is relevant in England, Northern Ireland, Scotland
and Wales, but implementation can vary across the
devolved administrations. Devolution is about the
transfer of power by a central government to local
or regional administrations. In the UK, there are
distinct legislatures and governments in Scotland,
Wales and Northern Ireland, which have powers over
a range of policy areas.2 The AMR strategies were
developed by The Department of Health and Social
Care (DHSC, previously the Department of Health),
the Department for Environment, Food and Rural
Affairs (DEFRA) and Public Health England (PHE) in
collaboration with the UK devolved administrations.
DHSC, DEFRA and PHE lead and coordinate the work
of various organisations across the UK; the process is
overseen by an interdepartmental High Level Steer-
ing group (HLSG). The devolved administrations are
responsible for the implementation of the strategy in
their own jurisdictions with some differences between
the animal, environment and human sectors. For ani-
mals and the environment, DEFRA has some UK-wide
responsibilities. For the human side, the imple-
mentation of the strategy is fully devolved. The UK
government commissioned an independent review
on AMR and the final report was published in 2016
with 10 recommendations, led by a call for a massive
global awareness campaign, improved hygiene and
infection prevention and a reduction in the unnec-
essary use of antimicrobials (AMs) in agriculture and
their dissemination into the environment.1 Based on
these recommendations, the UK government made
commitments across different sectors including the
reduction of AMU in food producing animals (FPAs)
and strengthening veterinary stewardship of antibi-
otics (ABs), particularly those of greatest importance
to human health.9 Some AB classes are categorised
by WHO as critically important antibiotics (CIAs) for
human use, of which quinolones, third- and fourth-
generation cephalosporins, macrolides, glycopeptides
and polymyxins are designated as ‘highest priority
critically important antibiotics’ (HPCIAs).10
Surveillance systems need regular evaluation to
ensure that they are operational, efficient and cost
effective.11 The evaluation of surveillance system from
a OH perspective allows to assess whether cross-
sectoral collaboration generates an added value.12
The expected outcomes of integrated surveillance for
AMR/AMU include increased understanding of AMR
epidemiology at the interface across human health,
animal health and the environment, and the changes
in policy and behaviours resulting from OH infor-
mation generated, which would lead ultimately to a
reduction on AMR as a result of these changes.13,14
2 https://assets.publishing.service.gov.uk/government/uploads/system/
uploads/attachment_data/file/770300/IntroductionToDevolution.pdf.
To be able to capture these values and assess cross-
sectoral collaboration in the surveillance system for
AMR and AMU in the UK, it is essential to have a
full understanding of the systems and the linkages. To
the authors’ knowledge, there is no overview available
that map and describe the various surveillance pro-
grammes for AMR and AMU in the UK and their link-
ages.
The aim of this study was to characterise and map
the current surveillance systems for AMR and AMU
in the UK and identify integration points in the sys-
tem. The findings would aid future evaluations of the
surveillance system for AMR/AMU in the UK from a
OH perspective.
METHODS
To describe the surveillance system, international
guidelines related to surveillance for AMR and AMU
were used. These include the standards described in
the OIE Terrestrial Animal Health Code15,16 that pro-
vide guidance for the development of national AMR
surveillance and monitoring programmes in FPAs and
food products and AMU in FPAs, and WHO guidance
for establishing AMR surveillance in humans and for
monitoring antimicrobial consumption (AMC).17,18
In animals, the data collected for AMR included the
followings: (1) Bacteria subjected to surveillance and
monitoring; (2) target animal species; (3) sampling
sources; (4) types of samples to be collected; (5)
antimicrobial susceptibility testing (AST); (6) inter-
pretation of data; (7) reference laboratory; and (8)
annual reports. For AMU in animals, information
was collected on (a) sources of antimicrobial data
and (b) types and reporting formats for AMU data.
For humans, AMR data collected included:(1) type of
surveillance; (2) priority pathogens for surveillance;
(3) pathogen-antimicrobial combinations targeted
for AMR surveillance; (4) sampling setting; (5) spec-
imens; (6) population covered; (7) test conducted;
(8) interpretation of results and (9) reporting. For
AMC, information was collected on: (a) data sources
for consumption estimates; (b) denominator data;
(c) Reporting metric and (d) contextual information
relating to data collection (include any relevant infor-
mation related to the data, for example if a group of
patients or facility types are not included).
To collate information on these different parame-
ters, a review of documents and literature was con-
ducted. First, official UK documents were consulted
such as the National Action Plans from 2013 and
2019; the UK AMR strategy annual progress reports;
and surveillance reports for AMR/AMU in humans,
animals and food across the four UK countries. The
list of references in gathered articles then lead to the
identification of further sources. Following an initial
review, a literature search was conducted in Google
to identify further sources in areas where there were
gaps. The search terms used were: “antimicrobial
resistance”, “antibiotic resistance”, “antimicrobial
use”, “antibiotic use”, “AMR”, “AMU”, “surveillance”,
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F I G U R E 1 Graphical overview of the statutory elements of the surveillance system for antimicrobial use and antimicrobial resistance in
the United Kingdom**.
Abbreviations: ResAlert: refers to the UK response to the identification of a resistant bacterial isolate from an animal considered to present
a potential risk to human or animal health; DEFRA: Department for Environment Food and Rural Affairs; DHSC: Department of Health and
Social Care; VMD: Veterinary Medicines Directorate; FSA: Food Standards Agency; APHA: Animal and Plant Health Agency; SRUC: Scotlands’s
Rural College; AFBI: Agri-Food and Biosciences Institute; PHE: Public Health England; HPS: Health Protection Scotland; PHW: Public Health
Wales; PHA: Public Health Agency; DARC: Defra Antibiotic Resistance Coordination; SGSS: Second Generation Surveillance System (in Eng-
land); CoSurv Information System in Northern Ireland; ECOSS: Electronic Communication of Surveillance in Scotland; Data Store System
in Wales; ECDC: European Centre for Disease Prevention and Control; EFSA: European Food Safety Authority; EMA: European Medicines
Agency; GLASS: Global Antimicrobial Resistance Surveillance System.
*Some of the isolates are submitted by Hospital Microbiology laboratories to a reference laboratory for confirmation and some of them are
sent to the national databases. **Usage data are submitted voluntarily by livestock sectors.
“monitoring”, “United Kingdom”, “UK”, “England”,
“Wales”, “Scotland” and “Ireland”. The review of
the literature was conducted in June 2018 and then
updated in December 2019. The surveillance activities
considered were those that are part of the official
structured surveillance system for AMR and AMU in
the UK. The documents selected were read in full to
extract the data required to describe the surveillance
system as explained above; in addition, information
was collected on the different stakeholders in the
surveillance system. The data collected were synthe-
sized to provide a detailed description of the different
surveillance programmes in humans, animals and
food; the key organisations involved; responsibilities
and linkages. An overview map of the surveillance sys-
tem was produced to provide a visual representation
of the structure of the system and identify integrating
points across sectors.
To validate the description of the surveillance pro-
grammes, two experts were consulted; one from
the human health sector and one from the animal
health sector. The experts were selected based on
their involvement and knowledge on AMR and AMU
surveillance in the UK; they were a Public Health Reg-
istrar with expertise on AMR and AMU surveillance
and a Lead Epidemiologist working on a government
lab on AMR surveillance in animals. The latter pro-
vided also feedback on AMR surveillance in food since
all the samples from food are meat samples. For the
environment, currently there is no official surveillance
programme for AMR in the environment in the UK;
therefore no expert was consulted from this sector.
During the meetings, the data tables and map gener-
ated were presented to the experts and they were asked
to provide feedback and identify potential gaps. Fol-
lowing this validation step, the description of the sys-
tem was revised and finalised.
RESULTS
Overview map of the surveillance system
for antimicrobial resistance and
antimicrobial use
We identified 30 key organisations directly involved
in the national surveillance system (Table 1). Out of
these, 15 belong to government organisations, nine
to the private sector and six to international institu-
tions. Figure 1 represents an overview map of the key
stakeholders, data collection streams, reporting and
the linkages in the system. The surveillance activi-
ties of AMR and AMU are organised in each sector
separately with presence of cross- sectoral integrated
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Department of Health and Social Care (DHSC) Human health
Department for Environment, Food and Rural Affairs (DEFRA) Animal, plant and
environment health
Veterinary Medicine Directorate (VMD) Animal health
Food Standards Agency (FSA) Food safety
Environment Agency (EA) Environment health
Public Health England (PHE) Human health
Health Protection Scotland (HPS) Human health
Public Health Wales (PHW) Human health
Public Health Agency (PHA) Human health
Animal and Plant Health Agency (APHA) Animal health
Agri-food and Bioscience Institute (AFBI) Animal health
Scotland’s Rural College (SRUC) Animal health
Centre for Environment, Fisheries and Aquaculture Science (CEFAS) Environment health (Aquatic
environment)
Hospitals Human health





British Veterinary Association (BVA) Animal health
Pharmaceutical companies Drug manufacturing and
distribution
Livestock stakeholders Animal production
Responsible Use of Medicines in Agriculture Alliance (RUMA) Animal production
Private veterinarians Animal health
Private laboratories Animal health
Vet Compass Animal health
Small Animal Veterinary Surveillance Network (SAVSNET) Animal health
The Agriculture and Horticulture Development Board (AHDB) Animal production
International
organisations
World Health Organisation (WHO) Human health
World Organisation for Animal Health (OIE) Animal health
Food and Agriculture Organisation (FAO) Animal health and food safety
European Centre for Disease Prevention and Control (ECDC) Human health
European Food Safety Authority (EFSA) Food safety
European Medicines Agency (EMA) Animal health
activities. Planning, data collection, analysis, inter-
pretation and reporting are conducted by each sec-
tor separately with the exception of Scotland where
there is an OH surveillance report (Scottish One
Health Antimicrobial Use and Antimicrobial Resis-
tance Report [SONAAR]).19 There are also variations
in the surveillance systems in the four UK countries,
especially in humans where the implementation of
the AMR strategy is fully devolved. In animals, there
is a UK wide annual surveillance report for AMR and
AMU, which is the Veterinary Antimicrobial Resistance
Surveillance (VARSS) report, while in humans there are
separate surveillance reports in each UK nation.
In terms of cross-sectoral collaboration, the most
important activity is the ResAlert contingency plan,
which refers to the response upon identification of
a resistant bacterial isolate from an animal consid-
ered to pose a potential risk to human and/or ani-
mal health.20 This is a UK wide plan initiated in
2015 and coordinated by the VMD in collaboration
with government agencies covering human and ani-
mal health, food safety and the devolved adminis-
trations. Depending on the hazard identified, rele-
vant advisory committees are notified by the relevant
agencies.20,21 Other examples of cross-sectoral collab-
orations include the UK OH reports and the DEFRA
Antimicrobial Resistance Coordination (DARC) group.
The UK OH report on human and animal antibiotic
use, sales and resistance was produced by PHE and
the VMD for the first time in 2015 and this helped to
align the data across sectors and included also recom-
mendations to address data limitations and to improve
integrated analyses.22 A second report was published
in 2019, which in addition to the data included in the
first report had also data on AMR in isolates from retail
meat.21 The DARC group coordinates, advises and
reviews DEFRA activities on AMU in animals and AMR
in micro-organisms from feedingstuffs, animals and
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food. This advisory group has representatives from sci-
ence and policy from England, Northern Ireland, Scot-
land and Wales covering human and animal health
and the environment.3
The UK contributes to European and Global surveil-
lance through different programmes that are repre-
sented as follows:
1. The European Antimicrobial Resistance Surveil-
lance Network (EARS-Net): Run by ECDC and col-
lects data on AMR in eight bacterial pathogens from
invasive infections in humans (Streptococcus pneu-
moniae, Staphylococcus aureus, Enterococcus fae-
calis, Enterococcus faecium, Escherichia coli, Kleb-
siella pneumoniae, Pseudomonas aeruginosa and
Acinetobacter spp.).23
2. The European Surveillance of Antimicrobial Con-
sumption Network (ESAC-Net): Run by ECDC and
collects data on the consumption of antimicrobial
agents in humans.23
3. The European Food and Waterborne Diseases
and Zoonoses Network (FWD-Net): Run by ECDC
and collects data on AMR in Salmonella spp.,
Campylobacter spp. and Shiga toxin/verocytotoxin-
producing E. coli (STEC/VTEC). The data
contribute to the EFSA/ECDC annual summary
report. To facilitate comparison of the data between
countries and with results from the AMR monitor-
ing performed in isolates from animals and food
products, EU protocol for harmonised monitoring
of AMR in human Salmonella and Campylobacter
isolates was developed by the ECDC.24,25
4. The EU harmonised monitoring of antibiotic resis-
tance in zoonotic and commensal bacteria from
healthy FPAs and food: Run by EFSA and collects
resistance data on Salmonella spp. and Campy-
lobacter spp. and indicator E. coli and Enterococcus
spp.24
5. The European Surveillance of Veterinary Antimi-
crobial Consumption (ESVAC): Run by EMA and
collects data on the use of antimicrobial agents in
animals.26
6. The Global Antimicrobial Resistance Surveillance
System (GLASS): Run by WHO and collects infor-
mation on resistance among human priority bacte-
rial pathogens from clinical specimens considered
a threat globally.18
The details of the sectoral structures and activities
are provided in the following sections.
Surveillance of antimicrobial use and
antimicrobial resistance in animals and
antimicrobial resistance in food
In animals, the veterinary antibiotic resistance and
sales data monitoring programme is commissioned
and funded by the VMD, which is an executive agency
3 https://www.gov.uk/government/groups/defra-antimicrobial-resistance-
coordination-darc-group.
of DEFRA. The VMD is also responsible for the pub-
lication of the VARSS report, which includes data
on antibiotic consumption (sales data and usage
data), and antibiotic resistance from animals in
the UK.9,27,28
Antibiotic consumption
Antibiotic sales data are submitted annually by Veteri-
nary pharmaceutical companies to the VMD; this has
been a statutory requirement since 2005. The data are
presented according to the Anatomical Therapeutic
Chemical Classification System for veterinary medici-
nal products (ATCvet) and analysed using a Population
Correction Unit (PCU). For usage data, the livestock
industry and VMD developed collaboratively antibi-
otic usage data collection systems.9 This initiative is
coordinated by RUMA;4 the UK agriculture and food
industry alliance that promotes responsible use of
medicines in farm animals. RUMA has 24 members
including the British Veterinary Association (BVA) and
the Agriculture and Horticulture Development Board
(AHDB). Antibiotic usage data refer to the amount
of ABs purchased, prescribed and/or administered.
Usage data are available for meat poultry (chicken,
turkey and duck), pigs, gamebirds, laying hens, dairy
sectors, beef, trout and salmon industries.27,28 Report-
ing coverage of AB use differs between sectors with
coverage of 90% or more for poultry, laying hens
and aquaculture sectors, 30% coverage for dairy and
5.5% in beef sector. For companion animals, antibi-
otic usage data are not systematically collected but the
VMD funded studies to investigate it and the results
were included in the UK-VARSS 2016.9,29,30 These
studies looked into AB prescriptions using the data
that were extracted from practice management sys-
tems by VetCompass and the Small Animal Veterinary
Surveillance Network (SAVSNET) system that are man-
aged by the Royal Veterinary College and the Univer-
sity of Liverpool, respectively. Antibiotic sales data in
dogs and cats were published in the UK-VARSS 2018.28
Antibiotic resistance
In England and Wales, antibiotic resistance data are
produced and collected by APHA. In Scotland and
Northern Ireland, this is done by SRUC Veterinary Ser-
vices and AFBI, respectively. APHA is a reference lab-
oratory for a range of infectious and non-infectious
diseases in animals. In 2018, a UK International Ref-
erence Centre (IRC) for AMR was established jointly
by APHA, VMD and Cefas. In 2019, this IRC was des-
ignated as an FAO Reference Centre for AMR.31 There
are two surveillance programmes for AMR: the EU
Harmonised Monitoring and the clinical surveillance
programme.9,27,28,32 A description of AMR data col-
lected from animals and food in the UK is presented
4 http://www.ruma.org.uk/wp-content/uploads/2017/10/RUMA-Targets-
Task-Force-Report-2017-FINAL.pdf.
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in Table 2. The list of the drug–bacteria combinations
tested is presented in Table S1.
The EU Harmonised Monitoring is a mandatory
surveillance programme (Commission Implementing
Decision 2013/652/EU5), which involves the test-
ing and reporting of resistance isolates of zoonotic
Salmonella spp., Campylobacter spp. and indicator
E. coli from healthy FPAs at farm and/or slaughter
and food products at retail. AST is carried out by the
national reference laboratories (NRLs) and standard-
ised methodologies are used.28 The sampling and test-
ing are organised following a rotation system. The
sampling size and strategy are designed to provide
a sample, which is representative of the wider pop-
ulation for each combination of bacteria and ani-
mal species. The competent authority in charge of
surveillance in food is the FSA. The collection of meat
samples at retail is conducted by FSA contractors,
and the analysis and interpretation are conducted by
APHA.33 In addition to publishing data from this pro-
gramme in the UK-VARSS report and in FSA reports for
retail meat, the results are also submitted to EFSA for
inclusion in the European Union Summary Report on
AMR in zoonotic and indicator bacteria obtained from
humans, FPAs and food.24
The clinical surveillance programme is based on
passive surveillance and involves the collection of
samples from carcasses or other diagnostic samples
that have been submitted to government laborato-
ries by farmers or private veterinary surgeons. When a
potential bacterial pathogen is identified, AST is con-
ducted. England and Wales have a combined clini-
cal surveillance programme and AST is performed by
APHA. Scotland and Northern Ireland conduct sepa-
rate clinical surveillance programmes and AST are per-
formed by SRUC Veterinary Services and AFBI, respec-
tively. The main aim of this programme is to provide
a diagnostic service for veterinarians, but it also helps
to identify new and emerging patterns of resistance.
Because samples are submitted voluntarily and repre-
sentativeness is not known, results cannot be extrapo-
lated to the whole livestock population.
In addition to the EU monitoring and clinical
surveillance programmes, ad hoc surveys are also
conducted to inform surveillance activities.34 Any
resistant bacterial isolate detected (through clinical
surveillance or EU statutory surveillance) and consid-
ered to pose a potential risk to human or animal health
is reported to the VMD for consideration and manage-
ment in accordance with the guidelines of the AMR
Contingency Plan (also known as the Res-Alert contin-
gency plan).20,28
Surveillance of antimicrobial use and
antimicrobial resistance in humans
The English Surveillance Programme for Antimicro-
bial Use and Resistance (ESPAUR) was established in
5 https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2013:303:
0026:0039:EN:PDF.
response to the UK government’s AMR strategy and
is led by PHE.23,35 In Scotland, the Control of Antimi-
crobial Resistance in Scotland (CARS) team in HPS is
in charge of delivering the UK AMR strategy.19,36 In
Northern Ireland and Wales, PHA and PHW, respec-
tively, are responsible for the implementation of the
strategy.37–39 A detailed description of antimicrobial
resistance data collected, data sources, tests con-
ducted, interpretative criteria and reporting is pre-
sented in Table 3. The full list of drug–bacteria com-
binations recommended for the monitoring of AMR as
a part of the UK AMR strategy is presented in Table S3.
Antibiotic consumption
Prescription data are collected from primary care and
secondary care in the four UK countries using a vari-
ety of systems. Antibiotics are prescribed in vari-
ous settings including general practice (GP), dental
practice, hospitals, out-of-hours services and walk-
in centres. The different sources of data and report-
ing are presented in Table S2 . Antibiotic consump-
tion data are classified based on the Anatomical
Therapeutic Chemical classification system, using the
WHO defined daily dose (DDD) per 1000 inhabitants
and per day. For the denominator, mid-year popu-
lation estimates are used to express DDDs per 1000
inhabitants/day. Data from private prescriptions dis-
pensed in the community and private hospitals are not
reported.22,35,40
Antibiotic resistance
To assess the impact of the strategy in slowing the
growth of AMR, data on resistance trends in key
bloodstream infections and gonorrhoea is monitored
using the proportion of resistant pathogens to spe-
cific antibiotics as an outcome measures. In each UK
country, AMR data are submitted voluntarily (pas-
sive surveillance) by microbiology laboratories and
collated in separate national databases. The four UK
countries all collect AMR data, but there are differ-
ences in data management. For example, in England,
the Second Generation Surveillance System (SGSS)
is maintained by PHE and contains data submit-
ted electronically by approximatively 98% of NHS
laboratories.19,38,39
DISCUSSION
This study showed that the surveillance system for
AMR and AMU has a multitude of stakeholders, pro-
cesses, activities, data sources, within the human, ani-
mal and food sectors. The graph and tables generated
provide an overview of the stakeholders involved in
the four UK countries in regulation, implementation
and governance; data collection streams, reporting,
linkages within and across sectors, and international
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monitoring. They allow drawing comparisons across
sectors and characterising existing integration and
opportunities for future integration. Consequently,
they form an important basis for any future evaluation
of the UK AMR/AMU surveillance system from a OH
perspective and are a resource for surveillance experts
working on the design of cross-sectoral systems.
Implications for surveillance system evaluations are
discussed below.
The study highlighted that there are variations in the
surveillance system for AMR and AMU between the
four UK nations, and identified integration points as
well as opportunities for further integration. In ani-
mals, surveillance of antibiotic consumption is mainly
based on sales data, however these data are an esti-
mate of the quantity of ABs used and do not enable
detailed analyses such as the consumption by animal
species or production system. Although AB usage data
are submitted voluntarily by some livestock stakehold-
ers, there are still substantial differences in reporting
coverage between livestock sectors. For AMR surveil-
lance in animals, one of the main programmes is the
EU harmonised monitoring. However, with the uncer-
tainties around Brexit, it is not known whether the
UK would continue to contribute to this programme.
In humans, surveillance of AMR is based on volun-
tary reporting by hospital microbiology laboratories.
Although there is a high reporting rate, weaknesses
of this system remain due to incomplete data col-
lection. Also, resistance data are collected from clin-
ical cases and do not include isolates from healthy
persons. Regarding AMU in humans, data from pri-
vate prescribers are not reported. Having a system
that captures data from private healthcare practices
is important to assess the extent of AMU from these
sources.
There is a lack of data from the environment,
which is considered to represent a significant path-
way for the transmission of AMR to humans and
animals.41 This has been acknowledged by the UK
government and one of the priorities in the new
AMR strategy is to understand better the role of the
environment in the spread of AMR.8 In addition, in
2018, a network of 23 partners (including UK gov-
ernment agencies APHA, Cefas, EA, PHE and VMD)
was awarded funding from the Joint Programme Ini-
tiative on AMR to identify robust, measurable surveil-
lance indicators and methodologies for assessing AMR
levels in the environment.6 The UK contributes also
to European and global surveillance through different
programmes.18,24,26,42 This collaboration helps har-
monise how the data are collected and shared and
allows comparison between countries. However, there
remain significant differences on how these data are
collected and analysed between the different sectors
including the use of different laboratory methods and
different interpretative criteria for resistance, which
hinders cross-sectoral comparisons.24,25
In the UK , each sector is responsible for the plan-
ning, implementation, analysis and reporting of its
6 https://www.jpiamr.eu/supportedprojects/7th-call-results/.
own surveillance for AMR and AMU, with presence of
cross-sectoral collaborative activities. These include:
(1) the availability of a UK wide AMR contingency
plan, which allows a timely response in the case of the
discovery of a resistance that poses a risk to human
or animal health; (2) the publication of the UK OH
reports, with the aim of supporting cross-sectoral
analyses; (3) the DARC group; and (4) the publica-
tion of an annual OH surveillance report in Scotland.
To strengthen integration, actions can be taken at
different levels. At the level of data collection, inte-
gration can be increased by including resistance data
from companion animals and from locations in the
environment; by including isolates from vegetables,
fruits and herbs; by collecting antibiotic usage data
from species that are not covered and by increasing
coverage in species with low coverage. Integration
can also be increased by harmonizing data analyses
methods and interpretation across sectors to enhance
the comparability of the information produced. This
was highlighted in the new AMR strategy and one of
the commitments is to “explore how to coordinate and
harmonise surveillance schemes across the different
sectors”.8 At the level of information dissemination,
integration can be increased by moving from pro-
ducing different surveillance reports for each sector
to integrating all surveillance information in a joint
report. Also, these surveillance reports need to include
data for the whole of the UK.
We are aware that these results are based on surveil-
lance activities that are part of the official surveillance
programmes for AMR and AMU in the UK and do not
include other non-official programmes, which consti-
tutes a limitation. On the other hand, these are the
main data used by the UK government to inform pol-
icy decisions and strategies on AMR and AMU. Also,
the integrated activities listed in this paper were based
on the activities reported in the documents reviewed
and other forms of collaboration that might be taking
place but not reported may have been missed.
Around the world, there are few countries with
combined analysis and reporting of an integrated
AMR/AMU surveillance programmes such as Den-
mark, Sweden, Canada and the Netherlands.5,43,44 For
example, the Danish Integrated Antimicrobial Resis-
tance Monitoring and Research Programme (DAN-
MAP) was established in 1995 as a collaboration
between the Ministry of Health and the Ministry of
Food, Agriculture and Fisheries and produces joint
annual reports.45 It is important to note that a greater
level of integration in a system does not necessary
result in a more cost-effective system. For this rea-
son, countries need to know how to achieve integra-
tion in a cost-effective manner. A conceptual frame-
work to assess the added value of OH surveillance for
AMR/AMU was developed in Canada, which provides
a conceptual basis for structuring the evaluation of dif-
ferent surveillance outcomes.13
Surveillance of AMR and AMU is crucial to provide
evidence for decisions to develop interventions to mit-
igate AMR, and to assess the effectiveness of these
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interventions by monitoring the rates of resistance
following their implementation. This study allowed
to characterise and map the surveillance system for
AMR/AMU in the UK from a OH perspective and iden-
tify integrating points. In addition, suggestions have
been made on opportunities for further integration.
Surveillance is expensive and appropriate resources
need to be allocated to integrated activities. To ensure
that the surveillance programmes are operational and
cost effective, regular evaluation is needed and an
evaluation of the system from a OH perspective is
essential to assess whether cross-sectoral collabora-
tion generates an added value. This work has created
a foundation for the evaluation of the performance of
the AMR/AMU integrated surveillance system in the
UK, an activity currently ongoing.
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